SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. is a biopharmaceutical company focused on developing treatments and drug delivery systems for patients with chronic eye conditions. Its primary product is the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which consists of novel drug pads attached to an intraocular lens (IOL). This system is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Additionally, the company is developing a non-IOL-based, ring-shaped, sustained-release implant containing bimatoprost. SpyGlass Pharma aims to provide long-term therapeutic benefits by combining cataract surgery with drug delivery, potentially improving patient compliance and outcomes.

SpyGlass Pharma, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SGP. The company's shares are traded in United States Dollars (USD). As a Nasdaq-listed company, SpyGlass Pharma is subject to the reporting and governance standards of the U.S. Securities and Exchange Commission, providing transparency for investors. The exchange listing and USD denomination make it accessible to both domestic and international investors through brokerage accounts that support U.S. equities.

SpyGlass Pharma, Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on research and development of innovative therapies, specifically in ophthalmology. The company's work involves combining pharmaceutical agents with medical devices to create drug-device combination products for chronic eye conditions. This places it at the intersection of biopharmaceuticals and medical technology, targeting unmet needs in the treatment of glaucoma and other eye diseases.

SpyGlass Pharma, Inc. is headquartered in Aliso Viejo, California, United States. The company was incorporated in 2019 and originally operated under the name SpyGlass Ophthalmics, Inc. before changing its name to SpyGlass Pharma, Inc. in April 2021. This name change reflected a broader focus on pharmaceutical development beyond ophthalmics. The company's location in California places it within a major biotechnology hub, providing access to talent, research collaborations, and a supportive ecosystem for innovation in medical technologies.

SpyGlass Pharma's business model centers on developing and commercializing drug-device combination products for chronic eye conditions. Its lead candidate, the BIM-IOL System, is designed to be implanted during cataract surgery, combining vision restoration with sustained drug delivery to lower intraocular pressure. This approach targets a large patient population undergoing cataract surgery who also have glaucoma or ocular hypertension. The company also has a pipeline product: a ring-shaped sustained-release implant with bimatoprost for patients not undergoing cataract surgery. Revenue would be generated through sales of these proprietary systems to hospitals, surgery centers, and ophthalmologists. As a development-stage biotech, the company currently focuses on clinical trials and regulatory approvals before commercialization.